-
1
-
-
0036401105
-
-
Wilhelm S CD: Bay 43-9006: Preclinical data. Curr Pharm Des 2002;8:2255-7.
-
Wilhelm S CD: Bay 43-9006: Preclinical data. Curr Pharm Des 2002;8:2255-7.
-
-
-
-
2
-
-
20044382799
-
Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43-9006 in patients with advanced refractory solid tumors
-
Strumberg D RH, Hilger R, et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72.
-
(2005)
J Clin Oncol
, vol.23
, pp. 965-972
-
-
Strumberg, D.R.1
Hilger, R.2
-
3
-
-
33744984843
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
-
Ratain M ET, Stadler W et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2505-2512
-
-
Ratain, M.E.1
Stadler, W.2
-
4
-
-
33748913369
-
Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma
-
364s Abstract
-
Gatzemeier U. GB FF, Simantov R, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. ASCO annual meeting Atlanta, Georgia. J Clin Oncol 2006;24:364s (Abstract #7002).
-
(2006)
ASCO annual meeting Atlanta, Georgia. J Clin Oncol
, vol.24
, Issue.7002
-
-
Gatzemeier, U.G.F.1
Simantov, R.2
-
5
-
-
33749017926
-
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
-
Ghassan K LS, Sergio R et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4293-4300
-
-
Ghassan, K.L.1
Sergio, R.2
-
6
-
-
33746649779
-
Phase I study of sorafenib, a raf kinase and vegfr inhibitor, combined with irinotecan in advanced solid tumors
-
Steinbild S BF, Gmehling D et al. Phase I study of sorafenib, a raf kinase and vegfr inhibitor, combined with irinotecan in advanced solid tumors. Proc Am Soc Clin Oncol 2005;23:3115a.
-
(2005)
Proc Am Soc Clin Oncol
, vol.23
-
-
Steinbild, S.B.1
Gmehling, D.2
-
7
-
-
38349179448
-
-
Eisen T AT, Gore ME et al. Phase I trial of sorafenib combined with dacarbazine in metastatic melanoma patients. Proc Am Soc Clin Oncol 2005;23:7508a.
-
Eisen T AT, Gore ME et al. Phase I trial of sorafenib combined with dacarbazine in metastatic melanoma patients. Proc Am Soc Clin Oncol 2005;23:7508a.
-
-
-
-
8
-
-
0020329356
-
Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous lekemia
-
Burgdorf W GW, Ganick R. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous lekemia. Ann Intern Med 1982;97:61-2.
-
(1982)
Ann Intern Med
, vol.97
, pp. 61-62
-
-
Burgdorf, W.G.1
Ganick, R.2
-
9
-
-
0021710953
-
Chemotherapy associated palmar-plantar erythrodysesthesia syndrome
-
Lokich J MC. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984;101:789-800.
-
(1984)
Ann Intern Med
, vol.101
, pp. 789-800
-
-
Lokich, J.M.1
-
10
-
-
0345596364
-
Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
-
MetaAnalysis Group in Cancer
-
MetaAnalysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-41.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3537-3541
-
-
-
11
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B ET, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007;356:125-34.
-
(2007)
New Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.E.1
Stadler, W.2
-
13
-
-
0022992740
-
Meta-analysis in clinical trials
-
DerSimonian R LN. Meta-analysis in clinical trials. Control Clin Trial 1986;7:177-88.
-
(1986)
Control Clin Trial
, vol.7
, pp. 177-188
-
-
DerSimonian, R.L.1
-
14
-
-
0030693603
-
Quantitative synthesis in systematic reviews
-
Lau J IJ, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
-
(1997)
Ann Intern Med
, vol.127
, pp. 820-826
-
-
Lau, J.I.1
Schmid, C.H.2
-
15
-
-
33748325763
-
-
Eiesen T AT, Flaherty K, et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.
-
Eiesen T AT, Flaherty K, et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.
-
-
-
-
16
-
-
38349160860
-
Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma
-
Atlanta, Georgia
-
Escudier B Sc DT, Staehler M, et al. Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma. ASCO annual meeting Atlanta, Georgia, 2006.
-
(2006)
ASCO annual meeting
-
-
Escudier, B.S.D.1
Staehler, M.2
-
17
-
-
38349119818
-
-
Wu S EP CS, P. M. Arlen, et al. Bay43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgenin-dependent prostate cancer despite rises in serum psa levels. 2006 Prostate Cancer Symposium San Fransisco, 2006 Abstract No:259.
-
Wu S EP CS, P. M. Arlen, et al. Bay43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgenin-dependent prostate cancer despite rises in serum psa levels. 2006 Prostate Cancer Symposium San Fransisco, 2006 Abstract No:259.
-
-
-
-
18
-
-
38349160860
-
Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma
-
Atlanta, Georgia
-
Escudier B Sc, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, et al. Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma. ASCO annual meeting. Atlanta, Georgia, 2006.
-
(2006)
ASCO annual meeting
-
-
Escudier, B.S.1
Demkow, T.2
Staehler, M.3
Rolland, F.4
Negrier, S.5
Hutson, T.E.6
-
19
-
-
38349141371
-
-
D'Adamo DR KM, Schuetze S, et al. A multicenter phase II trial of oral sorafenib in non-gist sarcomas ctep trial #7060. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:545s (Abstract #10001).
-
D'Adamo DR KM, Schuetze S, et al. A multicenter phase II trial of oral sorafenib in non-gist sarcomas ctep trial #7060. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:545s (Abstract #10001).
-
-
-
-
20
-
-
34548720158
-
Sorafenib improves survival in hepatocellular carcinoma: Results of a phase III randomized, placebo-controlled trial
-
1s Abstract #LBA1
-
Llovet J RS, Mazzaferro V, et al. Sorafenib improves survival in hepatocellular carcinoma: Results of a phase III randomized, placebo-controlled trial. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:1s (Abstract #LBA1).
-
(2007)
ASCO annual meeting Chicago, Illinois. J Clin Oncol
, vol.25
-
-
Llovet, J.R.1
Mazzaferro, V.2
-
21
-
-
38349150169
-
The advanced renal cell carcinoma sorafenib(arccs) expanded access program in North America: Safety and efficacy
-
237s Abstract
-
Figlin R SW, McDermott D, et al. The advanced renal cell carcinoma sorafenib(arccs) expanded access program in North America: Safety and efficacy. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:237s (Abstract #5011).
-
(2007)
ASCO annual meeting Chicago, Illinois. J Clin Oncol
, vol.25
, Issue.5011
-
-
Figlin, R.S.1
McDermott, D.2
-
22
-
-
38349109708
-
A phase II trial of sorafenib in patients with metastatic neuroendocrine tumors(net): A phase II consortium (p2c) study
-
199s Abstract
-
Hobday T RJ, Holen K, et al. A phase II trial of sorafenib in patients with metastatic neuroendocrine tumors(net): A phase II consortium (p2c) study. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:199s (Abstract #4504).
-
(2007)
ASCO annual meeting Chicago, Illinois. J Clin Oncol
, vol.25
, Issue.4504
-
-
Hobday, T.R.1
Holen, K.2
-
23
-
-
32444439875
-
Pooled safety analysis of bay 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
-
Strumberg DAA, Hirte H, et al. Pooled safety analysis of bay 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006;42:548-56.
-
(2006)
Eur J Cancer
, vol.42
, pp. 548-556
-
-
Strumberg, D.A.A.1
Hirte, H.2
-
24
-
-
0033122792
-
Capecitabine: Nursing implications of a new oral chemotherapeutic agent
-
Mrozek-Orlowski M FD, Sandborn H, et al. Capecitabine: Nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999;26:753-62.
-
(1999)
Oncol Nurs Forum
, vol.26
, pp. 753-762
-
-
Mrozek-Orlowski, M.F.1
Sandborn, H.2
-
25
-
-
25444472043
-
Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome?
-
Jacobi U WE, Schulze P. Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-1.
-
(2005)
Ann Oncol
, vol.16
, pp. 1210-1211
-
-
Jacobi, U.W.1
Schulze, P.2
-
26
-
-
33846924560
-
Hand-foot and stump syndrome to sorafenib
-
Lai S KT, Lacouture M. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007;25:341.
-
(2007)
J Clin Oncol
, vol.25
, pp. 341
-
-
Lai, S.K.1
Lacouture, M.2
-
27
-
-
33845313345
-
The clinical toxicity profile of vascular endothelial growth factor(vegf) and vascular endothelial growth factor receptor(vegfr) targeting angiogenesis inhibitors; a review
-
Eskens F VJ. The clinical toxicity profile of vascular endothelial growth factor(vegf) and vascular endothelial growth factor receptor(vegfr) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-39.
-
(2006)
Eur J Cancer
, vol.42
, pp. 3127-3139
-
-
Eskens, F.V.1
-
28
-
-
21344462378
-
Cutaneous side-effects of kinase inhibitors and blocking antibodies
-
Robert C SJ, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
-
(2005)
Lancet Oncol
, vol.6
, pp. 491-500
-
-
Robert, C.S.1
Spatz, A.2
-
29
-
-
33749251592
-
Increased efficacy and toxicity with combination anti-vegf therapy using sorafenib and bevacizumab
-
Azad N PE, Kohn E, et al. Increased efficacy and toxicity with combination anti-vegf therapy using sorafenib and bevacizumab. ASCO Annual Meeting Atlanta, Georgia. J Clin Oncol 2006;24:3004.
-
(2006)
ASCO Annual Meeting Atlanta, Georgia. J Clin Oncol
, vol.24
, pp. 3004
-
-
Azad, N.P.1
Kohn, E.2
-
30
-
-
1442290142
-
Combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms
-
Erber R TA, Katsen A, et al. Combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004;18:338-40.
-
(2004)
Faseb J
, vol.18
, pp. 338-340
-
-
Erber, R.T.1
Katsen, A.2
-
31
-
-
34247361171
-
Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma
-
Tsai K YC, Kuo T, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006;24:5786-8.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5786-5788
-
-
Tsai, K.Y.1
Kuo, T.2
-
32
-
-
34547852276
-
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot syndrome')
-
Lorusso D DSA, Carone V, et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot syndrome'). Ann Oncol 2007.
-
(2007)
Ann Oncol
-
-
Lorusso, D.D.1
Carone, V.2
-
33
-
-
0028280287
-
Epithelial-stromal interactions in basal cell cancer: The pdgf system
-
Ponten F RZ, Nister M, et al. Epithelial-stromal interactions in basal cell cancer: The pdgf system. J Invest Dermatol 1994;102:304-9.
-
(1994)
J Invest Dermatol
, vol.102
, pp. 304-309
-
-
Ponten, F.R.1
Nister, M.2
-
34
-
-
0028116487
-
Expression of c-kit and kit ligand proteins in normal human tissues
-
Lammie A DM, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-25.
-
(1994)
J Histochem Cytochem
, vol.42
, pp. 1417-1425
-
-
Lammie, A.D.1
Gerald, W.2
-
35
-
-
0028293816
-
Expression of c-kit ligand in human keratinocytes
-
Morita E LD, Sugiyama M, et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res 1994;286:273-7.
-
(1994)
Arch Dermatol Res
, vol.286
, pp. 273-277
-
-
Morita, E.L.1
Sugiyama, M.2
-
36
-
-
38349176975
-
Imatinib mesylate causes palmoplantar hyperkeratosis in 3 patients with chronic myeloid leukemia
-
Kawamura T DN, Shimizu A, et al. Imatinib mesylate causes palmoplantar hyperkeratosis in 3 patients with chronic myeloid leukemia. Br J Dermatol 2006;154:1199-219.
-
(2006)
Br J Dermatol
, vol.154
, pp. 1199-1219
-
-
Kawamura, T.D.1
Shimizu, A.2
-
37
-
-
38349184317
-
-
Hainsworth JD SJ, Spigel DR, et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma (rcc): A minnie pearl cancer research network phase I/II trial. ASCO Annual Meeting Orlando. 2005 Abstract # 4542.
-
Hainsworth JD SJ, Spigel DR, et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma (rcc): A minnie pearl cancer research network phase I/II trial. ASCO Annual Meeting Orlando. 2005 Abstract # 4542.
-
-
-
-
38
-
-
0037381437
-
Current Canadian experience with capecitabine: Partnering with patients to optimize therapy
-
Gerbrecht B. Current Canadian experience with capecitabine: Partnering with patients to optimize therapy. Cancer Nurs 2003;26:161-7.
-
(2003)
Cancer Nurs
, vol.26
, pp. 161-167
-
-
Gerbrecht, B.1
-
39
-
-
38349115491
-
-
Bayer. Nexavar prescribing information, 8/06 available at http://www.Nexavar.Com/wt/page/index. 2006.
-
Bayer. Nexavar prescribing information, 8/06 available at http://www.Nexavar.Com/wt/page/index. 2006.
-
-
-
-
40
-
-
0028784418
-
Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study
-
Bertelli G GA, Forno G, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol 1995;13:2851-5.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2851-2855
-
-
Bertelli, G.G.1
Forno, G.2
-
41
-
-
0035702431
-
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors
-
Eng C MA, Fleming G, et al. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol 2001;12:1743-7.
-
(2001)
Ann Oncol
, vol.12
, pp. 1743-1747
-
-
Eng, C.M.1
Fleming, G.2
-
42
-
-
0025217908
-
Pyridoxine therapy for palmar-plantar erythrodysesthesia assoicated with continuous 5-fluorouracil infusion
-
Fabian C MR, Lavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia assoicated with continuous 5-fluorouracil infusion. Invest New Drugs 1990;8:57-63.
-
(1990)
Invest New Drugs
, vol.8
, pp. 57-63
-
-
Fabian, C.M.1
Lavik, M.2
-
43
-
-
0027209407
-
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere
-
Vukelja S BW, Burris H, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993;85:1432-3.
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 1432-1433
-
-
Vukelja, S.B.1
Burris, H.2
-
44
-
-
3543080446
-
Oral dexamethasone attenuates pld-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies
-
Drake R LW, King M, et al. Oral dexamethasone attenuates pld-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004;94:320-4.
-
(2004)
Gynecol Oncol
, vol.94
, pp. 320-324
-
-
Drake, R.L.1
King, M.2
-
45
-
-
38349126085
-
Dramatic improvement of palmar plantar erythrodysesthesia(ppe) with oral prednisone
-
Elecronic letter
-
Jaber R DW, Wu S. Dramatic improvement of palmar plantar erythrodysesthesia(ppe) with oral prednisone. Ann Oncol 2007; Elecronic letter.
-
(2007)
Ann Oncol
-
-
Jaber, R.1
DW, W.S.2
-
46
-
-
0028266986
-
5-flourouracil dermatitis prophylaxis with a nicotine patch
-
Abstract
-
Kingsley E. 5-flourouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994;120:813 (Abstract).
-
(1994)
Ann Intern Med
, vol.120
, pp. 813
-
-
Kingsley, E.1
-
47
-
-
33744783431
-
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction
-
Kara I SB, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006;15:414-24.
-
(2006)
Breast
, vol.15
, pp. 414-424
-
-
Kara, I.S.1
Erkisi, M.2
-
48
-
-
0036985988
-
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity (Abstract)
-
Lin E MJ, Ayers G. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity (Abstract). Oncology 2002;16:31-7.
-
(2002)
Oncology
, vol.16
, pp. 31-37
-
-
Lin, E.M.1
Ayers, G.2
-
49
-
-
34247606548
-
-
Panares R GAea. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Therapy 2007;4:433-45.
-
Panares R GAea. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Therapy 2007;4:433-45.
-
-
-
-
51
-
-
33746591262
-
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
-
Morabito A DME, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 2006;11:753-64.
-
(2006)
Oncologist
, vol.11
, pp. 753-764
-
-
Morabito, A.D.1
Di Maio, M.2
-
52
-
-
33846181370
-
Sunitinib vs interferon alfa in metastatic renal cell cancer
-
Motzer R HT, Tomczak P, et al. Sunitinib vs interferon alfa in metastatic renal cell cancer. NEJM 2007;356:115-24.
-
(2007)
NEJM
, vol.356
, pp. 115-124
-
-
Motzer, R.H.1
Tomczak, P.2
-
53
-
-
33947423448
-
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerance in gastrointestinal stromal tumors and advanced renal cell cancer
-
Goodman V RE, Dagher R, et al. Approval summary: Sunitinib for the treatment of imatinib refractory or intolerance in gastrointestinal stromal tumors and advanced renal cell cancer. Clin Cancer Res 2007;13:1367-73.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1367-1373
-
-
Goodman, V.R.1
Dagher, R.2
|